Evolocumab Effect on Plaque Characteristics in Stable CAD Patients
Key Points The YELLOW III study aimed to assess the effect of 26 weeks of evolocumab on plaque morphology using intravascular imaging (OCT and NIRS/IVUS) and peripheral blood mononuclear cell…
No difference in Heart Failure Outcomes with Advanced Imaging modalities vs SPECT: The AIMI-HF Trial
Key Points: Imaging may be underused in patients with ischemic heart failure (HF) to evaluate ischemia/viability and guide management. The Alternative Imaging Modalities in Ischemic Heart Failure (AIMI-HF) Project directly…
Viability Not Linked to Survival or LV improvement: The REVIVED-BCIS2 Randomized Trial
Key Points: -It is unclear whether myocardial viability tests should be used to guide decisions about revascularization in patients with ischemic cardiomyopathy (ICMP). -The randomized trial REVIVED-BCIS 2 found that…
Atorvastatin Reduced Left Ventricular Dysfunction From Anthracyclines: The STOP-CA Trial
Key Points -Anthracycline therapy is associated with the development of heart failure, yet anthracyclines are among the most widely used and most effective antineoplastics. -Limiting the cumulative dose of…
CLEAR Outcomes – Bempedoic Acid reduces Cardiovascular Events among Statin-Intolerant Patients
Key Points Bempedoic acid, an ATP citrate lyase inhibitor, has been shown to reduce LDL cholesterol concentrations by 17% to 28% in clinical trials. However, data on whether bempedoic acid…
BrigHTN: Baxdrostat, an aldosterone synthase inhibitor, showed dose-related reductions in blood pressure and safely and effectively lowers blood pressure in patients with resistant hypertension
Key Points In a Phase 2 randomized trial, baxdrostat, a highly potent and selective aldosterone synthase inhibitor, had dose-related reductions in blood pressurein patients with resistant hypertension compared to placebo,…
FRESH –First-in-Class Aminopeptidase-A Inhibitor Firibastat Fails in Resistant Hypertension
Key Points Hypertension remains a major public health threat contributing significantly to rates of ischemic heart disease and strokes worldwide despite a wide array of antihypertensives available A new antihypertensive…
PRECISION –Dual Endothelin Receptor Antagonist Aprocitentan Superior to Placebo in Resistant Hypertension
Key Points Despite the many drug classes available to treat hypertension, the prevalence of resistant hypertension (hypertension requiring at least 3 blood pressure medications of different classes) points to significant…
RAPID – Self-Administered Etripamil Improves PSVT Conversion to Sinus Rhythm
Key Points -The RAPID study achieved its primary efficacy endpoint of terminating PSVT with self-administered Etripamil using a symptom-based optimal repeat dosing. -Pooled analysis with the NODE-301 study showed that…
NOVA – No significant difference in rate of post-op AF with botulinum toxin vs placebo
Key Points: -In a Phase II, dose-ranging trial of epicardial fat pad injection of botulinum toxin type A (AGN-151607) there was no significant differences in the rates of post-operative atrial…
OPTION –Indobufen is Noninferior to Aspirin After Coronary Drug-Eluting Stent Implantation
Key Points: Indobufen, a platelet aggregation inhibitor, has been shown to be a shorter acting antiplatelet in comparison to aspirin. However, it has not been studied as a component of…
PRECISE–A precision diagnostic strategy in patients with suspected CAD improves outcomes
Key Points: There is substantial heterogeneity in the use of different non-invasive and invasive modalities for CAD risk stratification; however, there limited is RCT evidence dictating the optimal strategy. In…
PRO-HF Sub-Study: Routine KCCQ-12 assessments in HF improves accuracy of provider assessment of patient health status.
Key Points Clinicians estimate heart failure (HF) health status using New York Heart Association (NYHA) class; however, this is often discordant with patient-reported symptom burden. The Patient-Reported Outcomes in Heart…
RAPCO: Radial artery grafting is superior to both RITA and SVG in patients undergoing CABG
Key Points: Recent guidelines have supported the use of arterial grafts over venous grafts in coronary artery bypass grafting (CABG), but there has yet to be a single randomized trial…
ECMO-CS: Early ECMO Does not Improve Outcomes in Severe Cardiogenic Shock
Key Points: ECMO has been used as a salvage strategy in severe cardiogenic shock. However, it is unclear whether immediate ECMO initiation is superior to an initial trial of medical…
CTS-AMI: Tongxinluo (TXL) improves CV outcomes in acute STEMI
Key Points: Tongxinluo (TXL) is a traditional Chinese medicine with endothelial-protective effects which has been used for angina and stroke prevention in China. It has yet to be tested as…
IRONMAN: Intravenous Ferric Derisomaltose did not not meet primary endpoint in HFrEF
Key Points: Iron deficiency is common and a poor prognostic feature in patients with heart failure. However, while iron infusion has improved symptoms in patients with HFrEF, there has been…
COACH – A Patient-Risk Based Health System Intervention for Acute Heart Failure Care: The Comparison of Outcomes and Access to Care for Heart Failure (COACH) Trial
Key Points: HF patients frequently present to the ED for acute exacerbations, and the decision whether to discharge, observe, or admit these patients can be complex. The COACH trial randomized…
First-in-Human in vivo Crispr/Cas9 Editing of the TTR Gene by NTLA-2001 in patients with Transthyretin Amyloid Cardiomyopathy
Key Points: Transthyretin Amyloidosis (ATTR) is a highly morbid and often fatal cause of cardiomyopathy. Existing therapies targeting TTR protein reduction have been effective, but have not managed to achieved…
The Diuretic Comparison Project (DCP): For hypertensive patients already on hydrochlorothiazide, switching to chlorthalidone does not improve outcomes
Key Points: Thiazide type diuretics are first-line medications for hypertension (HTN); while chlorthalidone (CTD) has been shown to lower blood pressure to a greater extent than hydrochlorothiazide (HCTZ), whether this…